Merck to Hold Second-Quarter 2014 Sales and Earnings Conference Call on July 29
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
will hold its second-quarter 2014 sales and earnings conference call
with institutional investors and analysts at 8:00 a.m. EDT on Tuesday,
July 29. During the call, company executives will provide an overview of
Merck’s performance for the quarter.
Language:
English
Contact:
...
Source: Merck.com - Corporate News - June 23, 2014 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck Names Michael J. Holston as Future General Counsel; Will Succeed Bruce N. Kuhlik in July 2015
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the future appointment of Michael J. Holston as general
counsel, effective July 01, 2015. Holston, who will also oversee
responsibility for Merck’s communications, policy and security
organizations beginning July 1 of this year, will succeed Bruce N.
Kuhlik upon his retirement after ten years with the company. Holston
will remain in his role as chief ethics an...
Source: Merck.com - Corporate News - June 23, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Begins Tender Offer to Acquire Idenix
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, is
commencing today, through a subsidiary, a cash tender offer to purchase
all outstanding shares of common stock of Idenix Pharmaceuticals, Inc.
(NASDAQ:IDIX). On June 09, 2014, Merck announced its intent to acquire
Idenix.
Language:
English
Contact:
Medi...
Source: Merck.com - Corporate News - June 20, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Launches Global Patient Registry Supporting Expanded Commitment to Real-World Outcomes Research in Type 2 Diabetes
Dateline City:
WHITEHOUSE STATION, N.J.
New Research Initiative Seeks to Identify Unmet Needs and Address Key Gaps in the Management of Type 2 Diabetes
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the launch of a global registry to evaluate the
experiences and outcomes of approximately 20,000 patients with type 2
diabetes in real-world settings over three years. The registry is part
...
Source: Merck.com - Corporate News - June 13, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck to Acquire Idenix
Dateline City:
WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass.
Acquisition Expands Portfolio of Promising Investigational Therapies for Hepatitis C
WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), today announced that the
companies have entered into a definitive agreement under which Merck
will acquire Idenix for $24.50 per share in cash. The tran...
Source: Merck.com - Corporate News - June 9, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck to Present New Clinical Data on JANUVIA® (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
will present 13 new studies and analyses, including data for its DPP-4
inhibitor JANUVIA® (sitagliptin) and for its
investigational once-weekly DPP-4 inhibitor omarigliptin, at the 74th
Scientific Sessions of the American Diabetes Association (ADA) being
held in San Francisco, June 13-17, 2014.
Several analyses of patient data in real-world settings will also be
...
Source: Merck.com - Corporate News - June 6, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
First Presentation of Data for Pembrolizumab, Merck’s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014
Dateline City:
CHICAGO
Initial Therapy with Pembrolizumab Demonstrates Robust Anti-Tumor Activity with Tumor Shrinkage in 80 Percent of Evaluable PD-L1 Positive, Advanced NSCLC Patients
Merck Initiating Phase 3 Study with Pembrolizumab Versus Platinum-Based Doublet Chemotherapy as First-Line Therapy in PD-L1 Positive, Advanced NSCLC (KEYNOTE-024)
Additional 50 Patients Enrolled in KEYNOTE-001 with Analyses Planned Using Merck’s Proprietary PD-L1 Assay at One Perc...
Source: Merck.com - Corporate News - June 2, 2014 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news
Data on Merck’s Pembrolizumab from Largest Study to Date of Investigational Anti-PD-1 Antibody in Advanced Melanoma Highlighted at ASCO 2014
Dateline City:
CHICAGO
Pembrolizumab as Monotherapy Shows Estimated Overall Survival Rate of 69 Percent at One Year Across 411 Advanced Melanoma Patients with Varying Stages of Disease and Prior Therapy
Durable Responses and Consistent Tolerability Profile Observed Across Doses, Including Patients With or Without Prior Ipilimumab Therapy
Phase 3 Trials Ongoing or Planned Across Lines of Therapy, Including Adjuvant Treatment
CHICAGO--(BUSINESS WIRE)...
Source: Merck.com - Corporate News - June 2, 2014 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news
First Presentation of Early Data for Pembrolizumab (MK-3475), Merck’s Investigational Anti-PD-1 Antibody, in Advanced Head and Neck Cancer at ASCO 2014
Dateline City:
CHICAGO
Overall Response Rate of 20 Percent for Pembrolizumab as Single Agent in Patients with Advanced Head and Neck Cancer
Merck Initiating Phase 3 Study in Advanced Head and Neck Cancer with Pembrolizumab Versus Standard of Care in Q3 2014 (KEYNOTE-040)
Additional 110 Patients with Advanced Head and Neck Cancer to be Enrolled in KEYNOTE-012 with Assessment of PD-L1 Tumor Levels Planned
Pembrolizumab Announced as New Generic Name for MK-3475
...
Source: Merck.com - Corporate News - June 1, 2014 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news
Merck Announces Third-Quarter 2014 Dividend
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Board of Directors has declared a quarterly
dividend of $0.44 per share of the company’s common stock for the third
quarter of 2014. Payment will be made on July 8, 2014, to stockholders
of record at the close of business on June 16, 2014.
About Merck
Language:
English
Contact...
Source: Merck.com - Corporate News - May 27, 2014 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe
Dateline City:
WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.
WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Endocyte, Inc.
Language:
English
Contact:
MerckMedia:Ian McConnell, +1 908-423-3046orClaire Mulhearn, +1 908-423-7425orInvestors:Carol Ferguson, +1 908-423-4465orJustin Holko, +1 908-423-5088orEndocyteMedia:Martina ...
Source: Merck.com - Corporate News - May 19, 2014 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news
The American College of Endocrinology & Merck Urge Patients with Type 2 Diabetes to Work with Their Doctor to Get to Their Blood Sugar Goals
Dateline City:
NEW YORK, N.Y.
Blood Sugar Basics Program Launches Three Easy-to-Follow “Missions” As Many Patients with Diabetes Are Not at Their A1C Goal [Despite Ongoing Efforts]
Today, the American College of Endocrinology (ACE), with support from Merck, known as MSD outside the United States and Canada, has launched the new Blood Sugar Basics: Get to Your Goals program to help educate the nearly 26 million Americans living with diabetes about proper blood sugar management. The Blood Sugar Basics: Get to...
Source: Merck.com - Corporate News - May 14, 2014 Category: Pharmaceuticals Tags: Corporate News Source Type: news
Merck’s Investigational Anti-PD1 Antibody, MK-3475, Active in Three Different Tumor Types: New Data to be Presented at the 2014 ASCO Annual Meeting
Dateline City:
WHITEHOUSE STATION, N.J.
Six oral presentations report MK-3475 monotherapy data across three different tumor types and multiple lines of therapy
Late-breaker presentation of long-term findings of MK-3475 in advanced melanoma, including ipilimumab-naïve and treated settings; data included in ASCO Press Program
First presentation of findings evaluating MK-3475 as initial treatment of patients with advanced non-small cell lung cancer ...
Source: Merck.com - Corporate News - May 14, 2014 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news
Merck Signs Sale Agreement with Santen for Merck’s Ophthalmology Products in Japan and Key Markets in Europe and Asia Pacific
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that it signed an agreement for Santen Pharmaceutical
Co., Ltd.
Language:
English
Contact:
MerckMedia:Caroline Lappetito, 267-218-1584orMamoru Ohara, 81-3-6272-1001orInvestor:Carol Ferguson, 908-423-4465
...
Source: Merck.com - Corporate News - May 13, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
FDA Approves ZONTIVITY™ (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease
Dateline City:
WHITEHOUSE STATION, N.J.
ZONTIVITY Added to Standard of Care Demonstrated Long-Term Benefit Through Three Years
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK),
known as MSD outside the United States and Canada, today announced that
the U.S. Food and Drug Administration (FDA) has approved ZONTIVITY™
(vorapaxar) for the reduction of thrombotic cardiovascular events in
patients with a history of heart attack (myocardial infarction) or in ...
Source: Merck.com - Corporate News - May 12, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
